Dear ASCCT members,
The next ASCCT webinar will be held in two weeks! Registration is now open for
the general public. Please register, if you haven’t already, and feel free to
send to your friends and colleagues. See below for more information.
Best wishes,
Kristie
Kristie Sullivan
Secretary, ASCCT
ksullivan@xxxxxxxxxxx<mailto:ksullivan@xxxxxxxxxxx>
Human Primary Cell-Based In Vitro Systems for Translational Drug Safety and
Mechanisms of Toxicity
May 31, 2016
2:00-3:00 PM US ET
Register here: https://attendee.gotowebinar.com/register/7611336632413987074
Presenter:
Ellen L. Berg, PhD
General Manager
BioSeek, a division of DiscoveRx
Abstract
Human cell-based in vitro assays that are physiologically relevant and also
amenable to large scale chemical testing are advancing our understanding of
toxicity mechanisms.
BioMAP® Systems are standardized panels of human primary cell-based and
co-culture assays that have been developed to model human tissue and disease
states. A large reference database of proteomic profiles, comprised of changes
in protein biomarker levels, has been developed using these systems for a set
of drugs and chemicals with known toxicities or adverse drug reactions (ADRs).
This reference dataset includes profiles of approved and failed drugs,
experimental chemicals, and compounds tested as part of the United States
Environmental Protection Agency¹s ToxCastTM program.
Examples where novel associations between assay biomarkers, target mechanisms,
and human ADRs have been identified include: (1) skin side effects induced by
MEK kinase inhibitors (e.g. trametinib, pimasertib and selumetinib), p38 MAPK
inhibitors, and the IL-1 receptor antagonist, anakinra; (2) thrombosis-related
side effects, associated with sirolimus, selective estrogen receptor modulators
and certain second generation anti-psychotic drugs; and (3) skin irritation
induced by retinoids and chemical vesicants.
By connecting mechanisms to ADRs, this data-driven approach is improving our
knowledge of toxicity mechanisms underlying adverse drug reactions and can also
contribute to the construction of adverse outcome pathway (AOP) frameworks.
After registering, you will receive a confirmation email containing information
about joining the webinar.
